Notice: This company has been marked as potentially delisted and may not be actively trading. ARCA biopharma (ABIO) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ARCA biopharma Short Interest DataARCA biopharma (ABIO) has a short interest of 4.99 million shares, representing 37.10% of the float (the number of shares available for trading by the public). This marks a 13.41% increase in short interest from the previous month. The short interest ratio (days to cover) is 50.3, indicating that it would take 50.3 days of the average trading volume of 607,995 shares to cover all short positions.Current Short Interest4,990,000 sharesPrevious Short Interest4,400,000 sharesChange Vs. Previous Month+13.41%Dollar Volume Sold Short$14.32 millionShort Interest Ratio50.3 Days to CoverLast Record DateAugust 15, 2024Outstanding Shares14,507,000 sharesFloat Size13,450,000 sharesShort Percent of Float37.10%Today's Trading Volume290,800 sharesAverage Trading Volume607,995 sharesToday's Volume Vs. Average48% Short Selling ARCA biopharma? Sign up to receive the latest short interest report for ARCA biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartABIO Short Interest Over TimeABIO Days to Cover Over TimeABIO Percentage of Float Shorted Over Time Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it ARCA biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/20244,990,000 shares $14.32 million +13.4%37.1%50.3 $2.87 7/31/20244,400,000 shares $13.20 million +4.0%32.4%49.8 $3.00 7/15/20244,230,000 shares $14.72 million +1.2%31.2%38 $3.48 6/30/20244,180,000 shares $16.01 million +1.0%30.8%30.9 $3.83 6/15/20244,140,000 shares $13.70 million No Change30.5%2.9 $3.31 5/31/20244,140,000 shares $15.32 million +1.0%30.5%2.9 $3.70 Get the Latest News and Ratings for ABIO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. 5/15/20244,100,000 shares $15.25 million No Change30.2%2.9 $3.72 4/30/20244,100,000 shares $14.31 million -27.6%30.2%2.9 $3.49 4/15/20245,660,000 shares $18.00 million +2,792.2%39.6%4.1 $3.18 3/31/2024195,700 shares $344,432.00 +6.6%1.4%0.1 $1.76 3/15/2024183,600 shares $310,284.00 +0.7%1.3%6.3 $1.69 2/29/2024182,300 shares $297,149.00 -1.9%1.3%6.9 $1.63 2/15/2024185,900 shares $306,735.00 -1.2%1.3%7.2 $1.65 1/31/2024188,100 shares $299,079.00 -3.3%1.3%7.5 $1.59 1/15/2024194,600 shares $317,198.00 -0.4%1.4%7.7 $1.63 12/31/2023195,400 shares $332,180.00 -7.9%1.4%8 $1.70 12/15/2023212,200 shares $371,350.00 +3.9%1.5%9.1 $1.75 11/30/2023204,300 shares $371,826.00 -4.7%1.4%9.5 $1.82 11/15/2023214,400 shares $375,200.00 -2.6%1.5%9.4 $1.75 10/31/2023220,100 shares $391,778.00 -9.8%1.6%9.6 $1.78 10/15/2023243,900 shares $496,336.50 +3.8%1.7%11.6 $2.04 9/30/2023234,900 shares $472,149.00 -11.4%1.7%11.9 $2.01 9/15/2023265,000 shares $543,250.00 +9.5%1.9%12.9 $2.05 8/31/2023242,000 shares $496,100.00 -7.0%1.7%10.5 $2.05 8/15/2023260,300 shares $531,012.00 +2.4%1.8%10.6 $2.04 7/31/2023254,300 shares $518,772.00 -4.0%1.8%10.2 $2.04 7/15/2023264,800 shares $534,896.00 -2.9%1.9%9.9 $2.02 6/30/2023272,700 shares $553,581.00 -1.2%1.9%10.6 $2.03 6/15/2023276,100 shares $579,810.00 +1.3%1.9%10 $2.10 5/31/2023272,600 shares $575,186.00 +0.6%1.9%10.6 $2.11 5/15/2023270,900 shares $560,763.00 +1.6%1.9%11.1 $2.07 4/30/2023266,600 shares $533,200.00 +8.7%1.9%11.1 $2.00 4/15/2023245,200 shares $490,890.40 -12.6%1.7%10.2 $2.00 3/31/2023280,400 shares $557,996.00 +23.9%2.0%9.7 $1.99 3/15/2023226,300 shares $491,071.00 -7.1%1.6%5.8 $2.17 2/28/2023243,500 shares $535,700.00 -2.2%1.7%6.3 $2.20 2/15/2023248,900 shares $522,690.00 -3.8%1.8%6.6 $2.10 1/31/2023258,600 shares $568,920.00 -9.0%1.8%6.7 $2.20 1/15/2023284,300 shares $666,683.50 -51.1%2.0%7.4 $2.35 12/30/2022581,500 shares $1.38 million +1,022.6%4.1%16.9 $2.37How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 12/15/202251,800 shares $120,176.00 -3.2%0.4%1.8 $2.32 11/30/202253,500 shares $111,815.00 +5.9%0.4%2 $2.09 11/15/202250,500 shares $101,000.00 -0.8%0.4%1.7 $2.00 10/31/202250,900 shares $109,435.00 -8.6%0.4%1.7 $2.15 10/15/202255,700 shares $114,185.00 -4.5%0.4%1.7 $2.05 9/30/202258,300 shares $120,098.00 -26.9%0.4%1.7 $2.06 9/15/202279,700 shares $186,498.00 +47.6%0.6%2 $2.34 8/31/202254,000 shares $126,360.00 -4.1%0.4%1.4 $2.34 8/15/202256,300 shares $137,935.00 -2.3%0.4%1.4 $2.45 7/31/202257,600 shares $141,120.00 -19.3%0.4%1.1 $2.45 7/15/202271,400 shares $177,786.00 -32.4%0.5%1.2 $2.49 6/30/2022105,600 shares $262,944.00 -26.1%0.7%1.4 $2.49 6/15/2022142,800 shares $324,156.00 -14.9%1.0%1.1 $2.27 5/31/2022167,700 shares $400,803.00 -17.4%1.2%1.1 $2.39 5/15/2022202,900 shares $468,699.00 -7.7%1.4%1.3 $2.31 4/30/2022219,900 shares $521,163.00 -4.6%1.5%1.4 $2.37 4/15/2022230,500 shares $539,370.00 -18.8%1.6%1.4 $2.34 3/31/2022283,700 shares $652,510.00 +21.4%2.0%1.7 $2.30 3/15/2022233,700 shares $504,792.00 -15.7%1.6%1.5 $2.16 2/28/2022277,100 shares $562,513.00 -8.0%1.9%1.7 $2.03 2/15/2022301,100 shares $566,068.00 -6.3%2.1%1.5 $1.88 1/31/2022321,200 shares $607,068.00 -1.2%2.3%1.4 $1.89 1/15/2022325,200 shares $656,904.00 +2.6%2.3%0.7 $2.02 12/31/2021316,900 shares $681,335.00 -13.9%2.2%0.7 $2.15 12/15/2021368,200 shares $850,542.00 -26.3%2.6%0.8 $2.31 11/30/2021499,700 shares $1.18 million +10.9%3.5%1.2 $2.37 11/15/2021450,700 shares $1.10 million +54.1%3.1%1.3 $2.44 10/29/2021292,500 shares $801,450.00 -1.6%2.0%0.9 $2.74 10/15/2021297,200 shares $829,188.00 -6.4%2.1%1.3 $2.79 9/30/2021317,600 shares $940,096.00 -18.3%2.2%1.2 $2.96 9/15/2021388,900 shares $1.17 million -3.6%2.7%1.4 $3.02 8/31/2021403,200 shares $1.25 million -1.5%2.8%1.4 $3.09 8/13/2021409,200 shares $1.19 million -8.7%2.9%1.3 $2.92 7/30/2021448,300 shares $1.42 million +16.3%3.1%1.3 $3.16 7/15/2021385,500 shares $1.15 million +14.2%2.7%1.6 $2.99 6/30/2021337,600 shares $1.18 million +41.2%2.4%1.3 $3.49 6/15/2021239,100 shares $899,016.00 -26.1%1.7%0.9 $3.76 5/28/2021323,400 shares $1.13 million -31.6%2.3%0.9 $3.49 5/14/2021472,700 shares $1.45 million +24.8%N/A0.8 $3.07 4/30/2021378,900 shares $1.33 million -31.9%N/A0.4 $3.50 4/15/2021556,700 shares $1.93 million +18.2%N/A0.6 $3.46 3/31/2021471,200 shares $1.66 million +45.1%N/A0.5 $3.52 3/15/2021324,700 shares $1.39 million +64.3%N/A0.3 $4.27 2/26/2021197,600 shares $867,464.00 +65.1%N/A0.2 $4.39 2/12/2021119,700 shares $634,410.00 +293.8%N/A0.1 $5.30 1/29/202130,400 shares $127,072.00 -62.6%N/A0.1 $4.18 1/15/202181,200 shares $363,776.00 -35.9%N/A0.2 $4.48 12/31/2020126,700 shares $516,936.00 +208.3%N/A0.3 $4.08 12/15/202041,100 shares $176,730.00 -17.5%N/A0.1 $4.30 11/30/202049,800 shares $213,144.00 +18.6%N/A0.1 $4.28How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 11/15/202042,000 shares $169,260.00 -18.3%N/A0.1 $4.03 10/30/202051,400 shares $198,918.00 -40.4%N/A0.1 $3.87 10/15/202086,300 shares $359,008.00 -40.8%N/A0.1 $4.16 9/30/2020145,800 shares $644,436.00 +169.0%N/A0.1 $4.42 9/15/202054,200 shares $283,466.00 -19.7%N/A0.1 $5.23 8/31/202067,500 shares $308,475.00 -23.2%N/A0.1 $4.57 8/14/202087,900 shares $523,005.00 +112.3%N/A0 $5.95 7/31/202041,400 shares $289,800.00 +88.2%N/A0 $7.00 7/15/202022,000 shares $142,120.00 -13.4%N/A0 $6.46 6/30/202025,400 shares $170,180.00 +63.9%N/A0 $6.70 6/15/202015,500 shares $110,515.00 +82.4%N/A0 $7.13 5/29/20208,500 shares $163,285.00 -62.7%N/A0 $19.21 5/15/202022,800 shares $88,008.00 -14.9%N/A1 $3.86 4/30/202026,800 shares $98,088.00 -18.3%N/A0.9 $3.66 4/15/202032,800 shares $145,632.00 -33.1%N/A1.1 $4.44 3/31/202049,000 shares $195,020.00 +23.7%N/A1.4 $3.98 3/13/202039,600 shares $118,800.00 +1,484.0%N/A1.7 $3.00 2/28/20202,500 shares $6,350.00 -59.0%N/A0.1 $2.54 2/14/20206,100 shares $20,191.00 +60.5%N/A0.1 $3.31 1/31/20203,800 shares $15,694.00 -13.6%N/A0.1 $4.13 1/15/20204,400 shares $23,540.00 -21.4%N/A0.1 $5.35 12/31/20195,600 shares $31,472.00 -36.4%N/A0.1 $5.62 ABIO Short Interest - Frequently Asked Questions What is ARCA biopharma's current short interest? Short interest is the volume of ARCA biopharma shares that have been sold short but have not yet been covered or closed out. As of August 15th, traders have sold 4,990,000 shares of ABIO short. 37.10% of ARCA biopharma's shares are currently sold short. Learn More on ARCA biopharma's current short interest. What is a good short interest ratio for ARCA biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABIO shares currently have a short interest ratio of 50.0. Learn More on ARCA biopharma's short interest ratio. What is a good short interest percentage for ARCA biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 37.10% of ARCA biopharma's floating shares are currently sold short. Is ARCA biopharma's short interest increasing or decreasing? ARCA biopharma saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 4,990,000 shares, an increase of 13.4% from the previous total of 4,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is ARCA biopharma's float size? ARCA biopharma currently has issued a total of 14,507,000 shares. Some of ARCA biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ARCA biopharma currently has a public float of 13,450,000 shares. How does ARCA biopharma's short interest compare to its competitors? 37.10% of ARCA biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ARCA biopharma: Telomir Pharmaceuticals, Inc. (4.69%), Puma Biotechnology, Inc. (8.35%), XBiotech Inc. (3.92%), Vaxart, Inc. (4.96%), Compugen Ltd. (1.48%), Enanta Pharmaceuticals, Inc. (17.08%), Monopar Therapeutics Inc. (0.55%), Tenaya Therapeutics, Inc. (25.43%), Atossa Therapeutics, Inc. (6.52%), Black Diamond Therapeutics, Inc. (11.31%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.23 billion), Aptiv PLC ($2.50 billion), Royal Caribbean Cruises Ltd. ($2.48 billion), Paychex, Inc. ($2.25 billion), Moderna, Inc. ($2.17 billion), Cencora, Inc. ($2.12 billion), Tractor Supply ($1.93 billion), Onsemi ($1.82 billion), International Paper ($1.81 billion), and Rivian Automotive, Inc. ($1.72 billion). View all of the most shorted stocks. What does it mean to sell short ARCA biopharma stock? Short selling ABIO is an investing strategy that aims to generate trading profit from ARCA biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ARCA biopharma? A short squeeze for ARCA biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABIO, which in turn drives the price of the stock up even further. How often is ARCA biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABIO, twice per month. The most recent reporting period available is August, 15 2024. More Short Interest Resources from MarketBeat Related Companies Telomir Pharmaceuticals Short Interest Puma Biotechnology Short Interest XBiotech Short Interest Vaxart Short Interest Compugen Short Interest Enanta Pharmaceuticals Short Interest Monopar Therapeutics Short Interest Tenaya Therapeutics Short Interest Atossa Therapeutics Short Interest Black Diamond Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ABIO) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
